<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816227</url>
  </required_header>
  <id_info>
    <org_study_id>C20-55</org_study_id>
    <secondary_id>2020-A03348-31</secondary_id>
    <nct_id>NCT04816227</nct_id>
  </id_info>
  <brief_title>Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments</brief_title>
  <acronym>Mac2ALS</acronym>
  <official_title>Expression Profile Study of Macrophages From Patients Affected by Amyotrophic Lateral Sclerosis (ALS) or Other Related Motor Impairments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to analyze the macrophage transcriptome and protein markers of&#xD;
      Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals,&#xD;
      patients with other motor impairments) and asymptomatic ALS gene carriers, to find new&#xD;
      pathways for therapeutic targets and disease biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults&#xD;
      affecting upper and lower motor neurons resulting in progressive muscle atrophy and paralysis&#xD;
      of the patients within 2 to 5 years. The majority of ALS cases are sporadic (SALS), 5 to 10%&#xD;
      are familial forms (FALS). In France, the most frequent mutation is an intronic&#xD;
      hexanucleotide expansion in the C9orf72 gene, representing 46% of FALS followed by mutations&#xD;
      in the first discovered ALS gene, SOD1 accounting for around 10% of FALS. Using mutant SOD1&#xD;
      ALS mouse models, the investigators and others have shown that motor neurons degenerated&#xD;
      through a non-cell autonomous mechanism involving microglial cells. Microglial cells are the&#xD;
      macrophages of the central nervous system (CNS) capable of producing neurotrophic or&#xD;
      neurotoxic factors. Microglial cells are part of the myeloid lineage like macrophages at the&#xD;
      periphery, however these two cell types have different developmental origins and are in&#xD;
      different environments. Spinal motor neurons are particular neurons since their cell body is&#xD;
      in the CNS, and therefore surrounded by microglial cells, while their axon extends at the&#xD;
      periphery and is therefore in contact with peripheral macrophages. The investigators have&#xD;
      shown that (i) peripheral macrophages in affected peripheral nerves of ALS mouse models and&#xD;
      ALS patient post-mortem tissues were activated, (ii) in ALS mouse models, both microglial&#xD;
      cells but also peripheral macrophages participated in disease progression and (iii)&#xD;
      peripheral macrophages were able to influence microglial cell reactivity.&#xD;
&#xD;
      The working hypothesis is that peripheral macrophages are themselves (and not just microglial&#xD;
      cells) involved in ALS and with this project the investigators want to compare macrophages&#xD;
      from ALS patients and controls using macrophages derived from blood monocytes. The aim is to&#xD;
      analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis&#xD;
      (ALS) patients compared to controls (non-affected individuals, patients with other motor&#xD;
      impairments) and asymptomatic ALS gene carriers, to find new pathways to target and disease&#xD;
      biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of transcriptome differences between the ALS group and the 3 other groups of participants.</measure>
    <time_frame>5 years</time_frame>
    <description>Will be considered different modulation superior or equal to 1.5 fold with a statistical value of p&lt;0.05.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Amyotrophic Lateral Sclerosis (ALS)</arm_group_label>
    <description>Blood draw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>asymptomatic carriers of ALS mutations</arm_group_label>
    <description>Blood draw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with motor impairment other than ALS</arm_group_label>
    <description>Blood draw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>Blood draw</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: Be affected by Amyotrophic Lateral Sclerosis (ALS) definite, probable or possible&#xD;
        (El Escorial criteria) sporadic SALS (no known history in the family) or familial FALS (at&#xD;
        least one other member of the family affected)&#xD;
&#xD;
        Group 2: Be a carrier of a known mutation causing ALS and be asymptomatic&#xD;
&#xD;
        Group 3: Have a motor impairment related to ALS including the following pathologies: Motor&#xD;
        neuropathy, myopathy, Myositis, Spastic paraplegia, Cram / fasciculation syndrome, Chronic&#xD;
        inflammatory polyradiculitis, somatization disorder, Anterior spinal artery syndrome,&#xD;
        encephalitis, myelitis, Peroneal neuropathy, cervical myelopathy with radiculopathy,&#xD;
        spinocerebellar ataxia, Kennedy disease, Spinal atrophy, Hereditary distal motor&#xD;
        neuropathy.&#xD;
&#xD;
        Group 4: Healthy control&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agree to participate in this research and have signed an informed consent&#xD;
&#xD;
          -  Be able to understand the objectives and procedures of the study&#xD;
&#xD;
          -  Be affiliated to French social security or equivalent&#xD;
&#xD;
          -  Meet one of the criteria below:&#xD;
&#xD;
             (i) Be affected by Amyotrophic Lateral Sclerosis (ALS) definite, probable or possible&#xD;
             (El Escorial criteria) sporadic SALS (no known history in the family) or familial FALS&#xD;
             (at least one other member of the family affected), (ii) not being affected by ALS but&#xD;
             having a close relative who has or has been diagnosed with ALS and has or is a carrier&#xD;
             of a known mutation causing ALS and has consented to a genetic analysis, (iii) Have a&#xD;
             motor impairment including the following pathologies: Motor neuropathy, myopathy,&#xD;
             Myositis, Spastic paraplegia, Cram / fasciculation syndrome, Chronic inflammatory&#xD;
             polyradiculitis, somatization disorder, Anterior spinal artery syndrome, encephalitis,&#xD;
             myelitis, Peroneal neuropathy, cervical myelopathy with radiculopathy, spinocerebellar&#xD;
             ataxia, Kennedy disease, Spinal atrophy, Hereditary distal motor neuropathy.&#xD;
&#xD;
        (iv) be accompanying a person with ALS or other motor impairment that is followed by one of&#xD;
        the doctors from the ALS referral center at the Pitié-Salpêtrière hospital or by a&#xD;
        neurologist from the neurophysiology department at the Pitié-Salpêtrière hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be subjected to a legal protection measure (safeguard of justice, curatorship or&#xD;
             guardianship)&#xD;
&#xD;
          -  Refusing to participate in the study&#xD;
&#xD;
          -  Whose condition, in the opinion of the doctor, is incompatible with blood draw or&#xD;
             participation in research&#xD;
&#xD;
          -  Being pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François SALACHAS, MD</last_name>
    <role>Study Director</role>
    <affiliation>APHP, Hôpital de la Salpêtrière, INSERM U1127, ICM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François SALACHAS, MD</last_name>
    <phone>+331 42 16 24 72</phone>
    <email>nathalie.cormand@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Severine BOILLEE, PhD</last_name>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

